ACOG: All women should be offered additional pre-pregnancy screening | RNA sequencing may reveal mutations not detected by DNA sequencing | Physician: Study suggests bigger role for CRC genetic testing
April 25, 2017
AACC SmartBrief
Top Story
ACOG: All women should be offered additional pre-pregnancy screening
All women, regardless of their ethnic background, should be offered additional carrier screening before pregnancy, according to a new opinion from the American College of Obstetricians and Gynecologists' Committee on Genetics. "[T]he pretest probability of being a carrier for a specific disorder may not be consistent with previous assumptions about the prevalence of that disorder in the various ethnic and racial groups with which a patient identifies," the opinion states.
Clinical Laboratory News (4/2017) 
LinkedIn Twitter Facebook Google+ Email
Science Briefs
RNA sequencing may reveal mutations not detected by DNA sequencing
Sequencing the RNA of skeletal muscle biopsies from patients with undiagnosed disorders revealed disease-causing genetic mutations in 17 of 50 patients, researchers reported in Science Translational Medicine. The researchers identified disease-causing mutations in the dystrophin gene in patients with Duchenne muscular dystrophy as well as a severe collagen VI-related myopathy intron mutation that had been missed in DNA sequencing.
The Scientist online (4/19) 
LinkedIn Twitter Facebook Google+ Email
Physician: Study suggests bigger role for CRC genetic testing
A study that included more than 1,000 colorectal cancer patients at the Dana-Farber Cancer Institute showed almost 10% had a mutation in a cancer susceptibility gene, suggesting genetic testing may have an expanded role in CRC, said Dr. Matthew Yurgelun, who led the research. Yurgelun said historically it was believed that inherited factors account for 3% to 4% of CRC patients.
Targeted Oncology (4/19) 
LinkedIn Twitter Facebook Google+ Email
Tech Briefs
Wearable device may help detect, monitor diabetes
A team of scientists at Stanford University developed a wristband-type wearable sensor that can diagnose and monitor diseases such as diabetes and cystic fibrosis by measuring the molecular constituents of sweat, according to a study published in the journal PNAS. The device can run with a smartphone, which can send the measurements to a center to be reviewed.
Business Standard (India) (tiered subscription model)/Press Trust of India (4/18) 
LinkedIn Twitter Facebook Google+ Email
Atomwise research uses AI to speed drug discovery
Atomwise launched its Artificial Intelligence Molecular Screen program, which employs algorithms that can screen millions of molecules per day. The program, open to US and Canadian researchers, hopes to find new drugs for such diseases as multiple sclerosis, leukemia and Ebola.
VentureBeat (4/19) 
LinkedIn Twitter Facebook Google+ Email
Policy Briefs
CMS sets deadline for comments on proposed EHR incentive program changes
The CMS will accept formal comments on proposed changes to the Medicare and Medicaid EHR Incentive Programs until June 13. These changes include revising the EHR reporting period from the full calendar year to any continuous 90-day period, implementing a policy that would not allow payment adjustments for eligible providers who conduct most of their professional services in ambulatory surgery centers, and adding a Medicare payment adjustment for eligible hospitals and professionals who cannot comply with meaningful-use requirements because of decertified technology. (4/24) 
LinkedIn Twitter Facebook Google+ Email
Practice Briefs
SpeeDx, Thermo Fisher partner to obtain FDA nod for STD assay
A partnership has been reached by Australian diagnostics company SpeeDx and Thermo Fisher Scientific to seek approval from the FDA for SpeeDx's ResistancePlus MG assay for antibiotic-resistant Mycoplasma genitalium. The deal, for which terms were not disclosed, calls for the test to be submitted by SpeeDx to the agency after successful validation of the product for use on Thermo Fisher's Applied Biosystems 7500 Fast Dx Real-Time-PCR system.
GenomeWeb Daily News (free registration) (4/24) 
LinkedIn Twitter Facebook Google+ Email
Business/Corporate Briefs
Abbott Laboratories, Alere end legal fight with $5.3B merger deal
Abbott Laboratories has ended months of legal fighting with Alere after agreeing to acquire Alere for about $5.3 billion, $500 million lower than the original price announced last year. The new $51-per-share agreement, which is expected to be completed by the end of the third quarter, will help expand Abbott's point-of-care testing assets.
Bloomberg (4/14),  Reuters (4/14) 
LinkedIn Twitter Facebook Google+ Email
GenDx, S. Korean company enter distribution deal for HLA assays
GenDx has reached an agreement with South Korean firm Infopia to distribute Infopia's GeneFinder human leukocyte antigen real-time PCR assays in Europe for undisclosed terms. GenDx will sell the kits through its local distributor network.
360Dx (tiered subscription model) (4/18) 
LinkedIn Twitter Facebook Google+ Email
Does your lab have the right strategy for cardiac troponin?
Improve your understanding of troponin testing and reporting, as well as expand collaborations with health care teams. Join AACC and Fred Apple, PhD, DABCC, to discuss the role of high-sensitivity cardiac troponin (cTn) assays to rule in/out myocardial injury and infarction in patients presenting with acute and chronic disease.
LinkedIn Twitter Facebook Google+ Email
Redefining the Value of Your Lab for Better Results
Join AACC and LabLeaders on May 3 for an engaging webinar that will focus on strategies laboratorians can use to clearly communicate the value of the laboratory testing services to payers and hospital administrators.
LinkedIn Twitter Facebook Google+ Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Christopher Black
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information